Literature DB >> 17516153

Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Kevin J Freise1, John A Widness, Robert L Schmidt, Peter Veng-Pedersen.   

Abstract

Most pharmacodynamic (PD) models of cellular response assume a time-invariant (i.e., constant) cellular disposition despite known changes in the disposition with time, such as the reticulocyte residence time in the systemic circulation during stress erythropoiesis. To account for changes in cellular disposition, a comprehensive PD model that involves endogenous erythropoietin (Epo), reticulocytes, and hemoglobin responses was developed in phlebotomized sheep that considers a time-variant reticulocyte residence time and allows for the simultaneous determination of changes in the cellular disposition and cellular production. Five sheep were phlebotomized to hemoglobin concentrations of approximately 4 g/dl. Epo concentrations, reticulocytes, and hemoglobin concentrations were frequently sampled for 5-7 days prior to and 25-30 days following the phlebotomy. Initial steady-state conditions were assumed and the time-variant reticulocyte residence time in the systemic circulation was semiparametrically represented using a constrained spline function. Hemoglobin production was modeled using a Hill function via an effect site compartment. The initial steady state reticulocyte residence time in the systemic circulation was estimated as 0.477 (0.100) (mean (SD)) days, which maximally increased 2.01- to 2.64-fold higher than the initial steady-state residence time 5.95 (0.899) days post-phlebotomy (P < 0.01). On average, the residence time returned to steady-state values 15.4 (2.36) days post-phlebotomy, which was not significantly different from the initial steady-state value (P > 0.05). The baseline hemoglobin production rate was estimated at 0.0929 (0.0472) g/kg/day and the maximum production rate under stress phlebotomy was estimated at 0.504 (0.0422) g/kg/day. These data indicate that endogenously released Epo under acute anemic conditions can increase hemoglobin production approximately 5-fold. The determined increase in reticulocyte residence time produced under stress erythropoiesis is similar to the commonly reported 2- to 3-fold increase observed in human patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17516153      PMCID: PMC2882108          DOI: 10.1007/s10928-007-9056-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  26 in total

1.  The maturation of reticulocytes. II. Life-span of red cells originating from stress reticulocytes.

Authors:  A Shimada
Journal:  Acta Med Okayama       Date:  1975-08       Impact factor: 0.892

Review 2.  Reticulocyte maturation.

Authors:  B Houwen
Journal:  Blood Cells       Date:  1992

3.  Circulating red cell volume and red cell survival can be accurately determined in sheep using the [14C]cyanate label.

Authors:  D M Mock; G L Lankford; L F Burmeister; R G Strauss
Journal:  Pediatr Res       Date:  1997-06       Impact factor: 3.756

4.  Flow cytometric reticulocyte quantification using thiazole orange provides clinically useful reticulocyte maturity index.

Authors:  B H Davis; N C Bigelow
Journal:  Arch Pathol Lab Med       Date:  1989-06       Impact factor: 5.534

Review 5.  Erythropoiesis: normal and abnormal.

Authors:  R S Hillman; C A Finch
Journal:  Semin Hematol       Date:  1967-10       Impact factor: 3.851

6.  Characteristics of marrow production and reticulocyte maturation in normal man in response to anemia.

Authors:  R S Hillman
Journal:  J Clin Invest       Date:  1969-03       Impact factor: 14.808

7.  Effect of chronic erythropoietin administration on plasma iron in newborn lambs.

Authors:  C Peters; M K Georgieff; P A de Alarcon; R T Cook; L F Burmeister; L S Lowe; J A Widness
Journal:  Biol Neonate       Date:  1996

Review 8.  Assessing erythropoiesis and the effect of erythropoietin therapy in renal disease by reticulocyte counting.

Authors:  M Pradella; I Cavill; G d'Onofrio
Journal:  Clin Lab Haematol       Date:  1996-12

9.  Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep.

Authors:  J A Widness; P Veng-Pedersen; N B Modi; R L Schmidt; D H Chestnut
Journal:  J Pharmacol Exp Ther       Date:  1992-06       Impact factor: 4.030

10.  Reticulocyte maturity as an indicator for estimating qualitative abnormality of erythropoiesis.

Authors:  K Watanabe; Y Kawai; K Takeuchi; N Shimizu; H Iri; Y Ikeda; B Houwen
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

View more
  10 in total

1.  A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms.

Authors:  Julia Korell; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-18       Impact factor: 2.745

2.  Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo; An Vermeulen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

Review 3.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

4.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

5.  Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy.

Authors:  Matthew Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-04-01       Impact factor: 3.922

6.  Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.

Authors:  Kevin J Freise; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-10-21       Impact factor: 2.745

7.  Models for the red blood cell lifespan.

Authors:  Rajiv P Shrestha; Joseph Horowitz; Christopher V Hollot; Michael J Germain; John A Widness; Donald M Mock; Peter Veng-Pedersen; Yossi Chait
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-04-02       Impact factor: 2.745

8.  Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants.

Authors:  Kevin J Freise; John A Widness; Peter Veng-Pedersen
Journal:  J Pharmacol Exp Ther       Date:  2009-10-06       Impact factor: 4.030

9.  Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-14       Impact factor: 2.745

10.  Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia.

Authors:  Nicholas J Savill; William Chadwick; Sarah E Reece
Journal:  PLoS Comput Biol       Date:  2009-06-26       Impact factor: 4.475

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.